BioMarin's increasing profitability is also ... Outside of the U.S. and in our larger strategic markets, such as Germany and Japan, we will continue to focus on early diagnosis and treatment ...

BioMarin's resources did not go unnoticed by ... compared to Voxzogo's once-a-day doses. Meanwhile, Japanese pharma Otsuka recently picked up a clinical-stage PKU asset from Jnana Therapeutics ...

BioMarin Pharmaceutical Inc. (NASDAQ ... Outside of the U.S. and in our larger strategic markets, such as Germany and Japan, we will continue to focus on early diagnosis and treatment of the ...

BioMarin Pharmaceutical Inc. (NASDAQ ... with Palynziq growing by 17% due to increased penetration in the US and Japan. Analysts believe that the ERT business could contribute to exceeding mid ...

BioMarin's enzyme replacement therapy (ERT) business, particularly Naglazyme and Palynziq, has shown strong growth. The enzyme business grew by 12% year-over-year in 2024, with Palynziq growing by 17% ...

In October, Krystal Biotech filed a new drug application with Japan’s Pharmaceuticals and ... In the past 30 days, estimates for BioMarin Pharmaceutical’s 2025 EPS have increased from $4. ...

March S&P 500 E-Mini futures (ESH25) are trending down -0.11% this morning as investors digested U.S. President Donald Trump’s latest tariff threats. President Trump said on Tuesday that he would ...

It has in-license agreement with BioMarin, Luxna Biotech ... The company was founded in 1781 and is headquartered in Tokyo, Japan.

Other haemophilia gene therapy developers – BioMarin and CSL – have also reported slow uptake with their products, and BioMarin said recently it will not try to expand access to its Roctavian ...

Japan's Otsuka Pharma has agreed to take control ... There are a couple of drug treatments available, namely BioMarin’s enzyme-based therapies Kuvan (sapropterin) or Palynziq (pegvaliase ...